Institutional members access full text with Ovid®

Share this article on:

Reining in nuclear factor-kappaB in skeletal muscle disorders

Shintaku, Jonathan; Guttridge, Denis C.

Current Opinion in Clinical Nutrition & Metabolic Care: May 2013 - Volume 16 - Issue 3 - p 251–257
doi: 10.1097/MCO.0b013e3283600e79
TRANSLATIONAL RESEARCH IN WASTING DISEASES: Edited by Vickie E. Baracos, Didier Attaix and Claude Pichard

Purpose of review Nuclear factor-kappaB (NF-κB) activation is associated with a wide range of muscle-related diseases. Here, we review the evidence implicating specific NF-κB components in different disease pathologies and discuss therapies designed to target aberrant NF-κB signaling for the treatment of those pathologies.

Recent findings Many components of the NF-κB signaling pathway contribute to muscle pathologies, presumably through activation of the transcription factor. In addition, an increasing number of upstream factors have been connected to disease progression. Genetic models and therapeutic approaches affecting these upstream targets associate with ameliorating disease progression.

Summary Dissecting the crosstalk between NF-κB, its upstream mediators, and other signaling pathways is vital to our understanding of how activation of this signaling pathway is mediated in various diseases. The strides made in therapeutically inhibiting the NF-κB pathway provide some promise for the treatment of these diseases.

aDepartment of Molecular Virology, Immunology and Medical Genetics

bMolecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, Ohio, USA

Correspondence to Denis C. Guttridge, PhD, Department of Molecular Virology, Immunology and Medical Genetics, 520 Biomedical Research Tower, 460 W 12th Avenue, Columbus, OH 43210, USA. Tel: +1 614 688 3137; e-mail:

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.